AKRO:NSD-Akero Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 21.22

Change

0.00 (0.00)%

Market Cap

USD 0.74B

Volume

0.09M

Avg Analyst Target

USD 33.50 (+57.87%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California. Address: 601 Gateway Boulevard, South San Francisco, CA, United States, 94080

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-24 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

N/A

USD131.81B 38.58 31.39
BNTX BioNTech SE

N/A

USD67.50B 15.50 10.94
REGN Regeneron Pharmaceuticals Inc

N/A

USD61.22B 10.34 7.53
VRTX Vertex Pharmaceuticals Incorpo..

N/A

USD47.61B 24.20 15.87
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

N/A

USD35.36B N/A N/A
SGEN Seagen Inc

N/A

USD31.19B 53.49 43.63
GMAB Genmab A/S

N/A

USD30.55B 78.60 8.55
ALNY Alnylam Pharmaceuticals Inc

N/A

USD23.60B N/A N/A
RPRX Royalty Pharma plc

N/A

USD22.77B 30.36 12.47

ETFs Containing AKRO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -17.75% 51% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.75% 51% F 23% F
Trailing 12 Months  
Capital Gain -19.13% 42% F 17% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.13% 42% F 16% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 12.88% 50% F 57% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 12.88% 50% F 55% F
Risk Return Profile  
Volatility (Standard Deviation) 30.40% 85% B 59% F
Risk Adjusted Return 42.37% 70% C- 59% F
Market Capitalization 0.74B 68% D+ 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 8.18 47% F 77% C+
Price/Book Ratio 3.40 50% F 41% F
Price / Cash Flow Ratio -10.45 59% F 72% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -58.76% 48% F 25% F
Return on Invested Capital -41.38% 58% F 20% F
Return on Assets -33.88% 31% F 9% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 18.93 4% F 2% F
Short Percent 12.65% 13% F 13% F
Beta 0.56 82% B- 83% B
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector